Analysis of @entity737 therapy in the XXXX ( @entity2132 ) Trial.

@entity1 @entity1165 @entity1457 @entity737 @entity2132 @entity2224 @entity4710 @entity943 @entity204 @entity855
INTRODUCTION: The @entity737 ( @entity737 ) is commonly used to treat @entity1 with documented sustained @entity1165 ( @entity1165 ) or @entity2224 ( @entity2224 ). @entity943 recurrence rates in these @entity1 are high, but which @entity1 will receive a therapy and the forms of @entity943 recurrence ( @entity1165 or @entity2224 ) are poorly understood. METHODS AND RESULTS: The therapy delivered by the @entity737 was examined in 449 @entity1 randomized to @entity737 therapy in the @entity2132 ( @entity2132 ) Trial. Events triggering @entity1457 or antitachycardia pacing ( @entity855 ) were reviewed for @entity943 diagnosis, clinical symptoms, activity at the onset of the @entity943 , and appropriateness and results of therapy. Both shock and @entity855 therapies were frequent by 2 years, with 68% of @entity1 receiving some therapy or having an @entity204 . An appropriate shock was delivered in 53% of @entity1 , and @entity855 was delivered in 68% of @entity1 who had @entity855 activated. The first @entity943 treated in follow-up was diagnosed as @entity1165 (63%), @entity2224 (13%), @entity4710 (18%), unknown @entity943 (3%), or due to @entity737 or inappropriate sensing (3%). Acceleration of an @entity943 by the @entity737 occurred in 8% of @entity1 who received any therapy. No physical activity consistently preceded @entity943 , nor did any single clinical factor predict the symptoms of the @entity943 . CONCLUSION: Delivery of @entity737 therapy in @entity2132 @entity1 was common, primarily due to @entity1165 . Inappropriate @entity737 therapy occurred frequently. Use of @entity737 therapy as a surrogate endpoint for @entity204 in clinical trials should be avoided.
